ABN 53 075 582 740

ASX ANNOUNCEMENT
30 June 2016

BIONOMICS TO TRIAL DRUG AGAINST POST-TRAUMATIC STRESS DISORDER

- *Trial to examine effects of Bionomics' drug candidate BNC210 on PTSD*
- *No current effective treatments for PTSD*
- *5-10% of population will suffer PTSD at some point*

ADELAIDE, Australia, 30 June 2016: Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, has initiated a Phase II clinical trial with its drug candidate BNC210 in adults suffering Post-Traumatic Stress Disorder (PTSD).

The study's primary objective is to determine whether BNC210 causes a decrease in symptoms of PTSD as measured by the globally-accepted Clinician-Administered PTSD Scale (CAPS-5). Secondary objectives include the determination of the effects of BNC210 on anxiety, depression, quality of life, and safety. This clinical study will recruit 160 subjects with PTSD at 8-10 clinical research centres throughout Australia and New Zealand. The study is a randomized, double-blind, placebo-controlled design with subjects to be treated over 12 weeks with BNC210 or placebo.

The Principal Investigator is Professor Jayashri Kulkarni from the Monash Alfred Psychiatry Research Centre in Melbourne, Australia.

PTSD is very common and its societal and economic burden extremely heavy. It is estimated that 5-10% of the general population will suffer from PTSD at some point in their lives.

There is a need for further and improved pharmacotherapy options for people with PTSD. Currently, only two drugs, the antidepressants paroxetine and sertraline, are approved for the treatment of PTSD. However, they have not been shown to ameliorate the full range of PTSD symptoms, and complete remission of symptoms is rare.

Bionomics has also recently completed recruitment to a Phase II clinical study examining the biological effects of BNC210 on the brain, in subjects with Generalized Anxiety Disorder (GAD). The results of this study will be known in Q3 2016.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia
Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US
Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About BNC210
BNC210 is a first-in-class compound for the treatment of anxiety that lacks the side effect profile of current therapies such as benzodiazepines, selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. BNC210 works by negative allosteric modulation of the alpha 7 nicotinic acetylcholine receptor which is a key target for anxiety.

About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Clinical Trial Appendix

STUDY REFERENCE	RESTORE Protocol Number: BNC210.007
STUDY TITLE	A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults with Post-Traumatic Stress Disorder (PTSD).
PRIMARY OBJECTIVES	To assess the effects of BNC210 on investigator-rated symptoms of PTSD measured by Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) scores.
SECONDARY OBJECTIVES	To assess the effects of BNC210 on other psychiatric outcomes in subjects with PTSD including anxiety and depression. To assess the effects of BNC210 on global functioning and Quality of Life in subjects with PTSD. To assess the effects of BNC210 on patient-reported outcomes in subjects with PTSD. To assess the safety and tolerability of BNC210 in subjects with PTSD.
EXPLORATORY OBJECTIVES	To determine potential for maintenance of effects of BNC210 in subjects with PTSD in the 12-week follow-up period. To determine possible correlations between soluble biomarkers and effects of BNC210. To determine possible correlations between variations in genotype and effects of BNC210.
BLINDING STATUS	Double-blinded
TREATMENT METHOD	This is a randomized, double-blind, parallel, placebo-controlled, multicentre study with a 12-week, 2-arm treatment phase (Placebo and BNC210). BNC210 (600 mg) or Placebo will be taken twice daily (bid) with food for 12 weeks. Follow-up visits will be conducted at 4 and 12 weeks post-treatment.
TRIAL SUBJECT NUMBER	A total of 160 patients with PTSD will be enrolled in the study at a 1:1 ratio (80 subjects per treatment arm).
CONTROL GROUP	Placebo
SUBJECT SELECTION CRITERIA	Male and female subjects diagnosed with current PTSD as defined by the CAPS-5 for DSM-5.
TRIAL LOCATION	Approximately 8-10 centres located in Australia and New Zealand
CLINICAL TRIAL HISTORY	BNC210 has been evaluated in 7 clinical trials and 216 subjects to date: 1. BNC210.001: Single Ascending Doses Study - Australia 2. BNC210.002: Fed and Fasted Study - Australia 3. BNC210.003: Lorazepam Comparison and EEG Study, cognition as primary end point - France 4. BNC210.004: CCK Challenge - France 5. Single Ascending Doses Study – USA 6. BNC210.005: Multiple Ascending Doses Study – France 7. BNC210.006: Functional MRI in Generalized Anxiety Disorder - England